Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiproliferati...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8;155:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiprolife...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8;155:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiprolife...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8;155:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiprolife...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8;155:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiprolife...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8;155:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiprolife...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group
This study investigated changes in treatment modalities and outcomes of chronic myeloid leukemia in the chronic phase (CP-CML) after the approval of second-generation tyrosine kinase inhibitors (2G-TKIs) for first-line therapy. Patients were grouped into those who underwent TKI therapy up to December 2010 (imatinib era group, n = 185) and after January 2011 (2G-TKI era group, n = 425). All patients in the imatinib era group were initially treated with imatinib, whereas patients in the 2G-TKI era group were mostly treated with dasatinib (55%) or nilotinib (36%). However, outcomes including progression-free survival, overall...
Source: International Journal of Hematology - April 8, 2024 Category: Hematology Authors: Noriyoshi Iriyama Eisaku Iwanaga Yuta Kimura Naoki Watanabe Maho Ishikawa Hitomi Nakayama Eriko Sato Takayuki Tabayashi Toru Mitsumori Tomoiku Takaku Tomonori Nakazato Michihide Tokuhira Hiroyuki Fujita Miki Ando Yoshihiro Hatta Tatsuya Kawaguchi Source Type: research
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group
This study investigated changes in treatment modalities and outcomes of chronic myeloid leukemia in the chronic phase (CP-CML) after the approval of second-generation tyrosine kinase inhibitors (2G-TKIs) for first-line therapy. Patients were grouped into those who underwent TKI therapy up to December 2010 (imatinib era group, n = 185) and after January 2011 (2G-TKI era group, n = 425). All patients in the imatinib era group were initially treated with imatinib, whereas patients in the 2G-TKI era group were mostly treated with dasatinib (55%) or nilotinib (36%). However, outcomes including progression-free survival, overall...
Source: International Journal of Hematology - April 8, 2024 Category: Hematology Authors: Noriyoshi Iriyama Eisaku Iwanaga Yuta Kimura Naoki Watanabe Maho Ishikawa Hitomi Nakayama Eriko Sato Takayuki Tabayashi Toru Mitsumori Tomoiku Takaku Tomonori Nakazato Michihide Tokuhira Hiroyuki Fujita Miki Ando Yoshihiro Hatta Tatsuya Kawaguchi Source Type: research
A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens
Hematology. 2024 Dec;29(1):2335856. doi: 10.1080/16078454.2024.2335856. Epub 2024 Apr 6.ABSTRACTPhiladelphia chromosome-positive acute lymphoblastic leukemia (PH + ALL) is the most common cytogenetic abnormality of B-ALL in adults and is associated with poor prognosis. Previously, the only curative treatment option in PH + ALL was allogeneic hematopoietic stem cell transplantation (Allo-HSCT). Since 2000, targeted therapy combined with chemotherapy, represented by the tyrosine kinase inhibitor Imatinib, has become the first-line treatment for PH + ALL. Currently, the remission rate and survival rate of Imatinib are superio...
Source: Hematology - April 6, 2024 Category: Hematology Authors: Zhen-Yu Xiong Yao-Jia Shen Shi-Zhong Zhang Hong-Hu Zhu Source Type: research
Maternal and Foetal Outcomes of Newly Diagnosed Chronic Myeloid Leukemia During Pregnancy and its Long-Term Impact
This study aimed to assess pregnancy, foetal, and long-term disease outcomes in female patients newly diagnosed with CML in the chronic phase (CML-CP) during pregnancy. A retrospective analysis was conducted on female CML-CP patients presenting between January 2002 and December 2022 at our institution. Inclusion criteria encompassed patients newly diagnosed with CML-CP during pregnancy. Data pertaining to pregnancy outcomes, foetal development, and disease progression were analysed through a comprehensive review of medical records. Among the female CML patients, thirteen were diagnosed with CML-CP during pregnancy. The med...
Source: Indian Journal of Hematology and Blood Transfusion - April 5, 2024 Category: Hematology Source Type: research
Rapamycin vs TORin-1 or Gleevec vs Nilotinib: Simple chemical evolution that converts PAK1-blockers to TOR-blockers or vice versa?
Drug Discov Ther. 2024 Apr 4. doi: 10.5582/ddt.2023.01097. Online ahead of print.ABSTRACTBoth PAK1 (RAC/CDC42-activating kinase 1) and TOR (Target of Rapamycin) are among the major oncogenic/ageing kinases. However, they play the opposite role in our immune system, namely immune system is suppressed by PAK1, while it requires TOR. Thus, PAK1-blockers, would be more effective for therapy of cancers, than TOR-blockers. Since 2015 when we discovered genetically that PDGF-induced melanogenesis depends on "PAK1", we are able to screening a series of PAK1-blockers as melanogenesis-inhibitors which could eventually promote longev...
Source: Drug Discoveries and Therapeutics - April 3, 2024 Category: Drugs & Pharmacology Authors: Hiroshi Maruta Hong He Source Type: research
